Сравнение на методи
Прегледайте избраните методи един до друг; редовете с разлики са откроени.
| Фармакокинетичен компартментен модел× | Популационна фармакокинетика× | |
|---|---|---|
| Област | Фармакометрия | Фармакометрия |
| Семейство | Regression model | Regression model |
| Година на възникване≠ | 1982 | 1977 |
| Създател≠ | Gibaldi & Perrier | Sheiner, Rosenberg & Marathe |
| Тип≠ | Deterministic ODE-based pharmacokinetic model | Nonlinear mixed-effects regression model |
| Основополагащ източник≠ | Gibaldi, M., & Perrier, D. (1982). Pharmacokinetics (2nd ed.). Marcel Dekker. ISBN: 978-0-8247-1042-2 | Sheiner, L. B., Rosenberg, B., & Marathe, V. V. (1977). Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. Journal of Pharmacokinetics and Biopharmaceutics, 5(5), 445–479. DOI ↗ |
| Други названия | Mammillary Compartment Model, Multi-Compartment PK Model, Compartmental Analysis, Farmakokinetik Kompartman Modeli | PopPK, Nonlinear Mixed-Effects Modeling, NONMEM Approach, Popülasyon Farmakokinetiği |
| Свързани≠ | 3 | 2 |
| Резюме≠ | The pharmacokinetic compartment model represents the body as one or more hypothetical compartments interconnected by first-order rate processes, describing how a drug is absorbed, distributed, and eliminated over time. Systematized by Gibaldi and Perrier in 1982, these models use ordinary differential equations to characterize plasma concentration-time profiles. They are the cornerstone of drug development, dosage regimen design, and regulatory submission pharmacokinetic analyses. | Population Pharmacokinetics (PopPK) is a nonlinear mixed-effects modeling framework that characterizes how drugs are absorbed, distributed, metabolized, and eliminated across a patient population, estimating both typical population parameters and the magnitude of between-subject variability. Introduced by Sheiner, Rosenberg, and Marathe in 1977, it enables parameter estimation from sparse, routinely collected clinical data—making it indispensable in drug development, regulatory submissions, and individualized dosing. |
| ScholarGateНабор от данни ↗ |
|
|